AR039632A2 - Uso de un compuesto tipo amina heterociclica para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica - Google Patents
Uso de un compuesto tipo amina heterociclica para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronicaInfo
- Publication number
- AR039632A2 AR039632A2 ARP030101258A ARP030101258A AR039632A2 AR 039632 A2 AR039632 A2 AR 039632A2 AR P030101258 A ARP030101258 A AR P030101258A AR P030101258 A ARP030101258 A AR P030101258A AR 039632 A2 AR039632 A2 AR 039632A2
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkyl
- ch2cf3
- alkynyl
- alkenyl
- Prior art date
Links
- -1 AMINE COMPOUND Chemical class 0.000 title abstract 10
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title abstract 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 4
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 abstract 1
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 150000003852 triazoles Chemical class 0.000 abstract 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El uso de un compuesto tipo amina heterocíclica de fórmula (1), o de una de sus sales farmacéuticamente aceptables, que es para preparar un medicamento para el tratamiento de síntomas del síndrome de fibromialgia o síndrome de fatiga crónica, en donde: n es 0-3; R1 y R2 son independientemente H (siempre que solamente uno sea H a la vez), -OH, (siempre que R4 no sea hidrógeno), CN, CH2CN, 2- ó 4-CF3, CH2CF3, CH2CHF2, CH=CF2, (CH2)2CF3, etenilo, 2-propenilo, OSO2CH3, OSO2CF3, SSO2CF3, COR4, COOR4, CON(R4)2, SOxCH3 (donde x es 0-2), SOxCF3, O(CH2)xCF3, SO2N(R4)2, CH=NOR4, COCOOR4, COCOON(R4)2, C1-8 alquilo, C3-8 cicloalquilo, CH2OR4, CH2(R4)2, NR4SO2CF3, NO2, halógeno, un fenilo en las posiciones 2, 3 ó 4, tienilo, furilo, pirrol, oxazol, tiazol, N-pirrolina, triazol, tetrazol o piridina; R3 es hidrógeno, CF3, CH2CF3, C1-8 alquilo, C3-8 cicloalquilo, C4-9 cicloalquil-metilo, C2-8 alquenilo, C2-8 alquinilo, 3,3,3-trifluoropropilo, 4,4,4-trifluorobutilo, -(CH2)m-R5 (donde m es 1-8), CH2SCH3 o un C4-8 alquilo unido a dicho nitrógeno y a uno de sus átomos de carbono adyacentes inclusive, formando una estructura cíclica-; R4 es independientemente hidrógeno, CF3, CH2CF3, C1-8 alquilo, C3-8 cicloalquilo, C4-9 cicloalquil-metilo, C2-8 alquenilo, C2-8 alquinilo, 3,3,3- trifluoropropilo, 4,4,4-trifluorobutilo, -(CH2)m-R5 donde m es 1-8; R5 es fenilo, fenilo (sustituido con un CN, CF3, CH2CF3, C1-8 alquilo, C3-8 cicloalquilo, C4-9 cicloalquil-metilo, C2-8 alquenilo, C2-8 alquinilo), 2-tiofenilo, 3-tiofenilo, -NR6CONR6R7, o -CONR6R7; R6 y R7 son independientemente hidrógeno, C1-8 alquilo, C3-8 cicloalquilo, C4-9 cicloalquil-metilo, C2-8 alquenilo o C2-8 alquinilo; y con la condición de que cuando R1 es 2-CN ó 4-CN, R2 es H, R3 es n-Pr y n es 1 ó 3, entonces ese compuesto es un enantiómero puro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19895900P | 2000-04-21 | 2000-04-21 | |
| US20056900P | 2000-04-28 | 2000-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039632A2 true AR039632A2 (es) | 2005-03-02 |
Family
ID=26894316
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101861A AR028355A1 (es) | 2000-04-21 | 2001-04-20 | Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
| ARP030101259A AR039633A2 (es) | 2000-04-21 | 2003-04-10 | Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
| ARP030101258A AR039632A2 (es) | 2000-04-21 | 2003-04-10 | Uso de un compuesto tipo amina heterociclica para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101861A AR028355A1 (es) | 2000-04-21 | 2001-04-20 | Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
| ARP030101259A AR039633A2 (es) | 2000-04-21 | 2003-04-10 | Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US6448258B2 (es) |
| EP (1) | EP1274430B1 (es) |
| JP (1) | JP2004502650A (es) |
| KR (1) | KR20040007215A (es) |
| CN (3) | CN1450898A (es) |
| AR (3) | AR028355A1 (es) |
| AT (1) | ATE312608T1 (es) |
| AU (2) | AU5311401A (es) |
| BR (1) | BR0110210A (es) |
| CA (1) | CA2405565A1 (es) |
| DE (1) | DE60115872T2 (es) |
| DK (1) | DK1274430T3 (es) |
| ES (1) | ES2253370T3 (es) |
| NZ (3) | NZ531172A (es) |
| PE (1) | PE20011212A1 (es) |
| WO (1) | WO2001081343A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| BR0110188A (pt) * | 2000-04-21 | 2003-03-05 | Upjohn Co | Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica |
| AR033520A1 (es) * | 2000-04-27 | 2003-12-26 | Upjohn Co | (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona |
| KR20030024877A (ko) * | 2000-08-16 | 2003-03-26 | 파마시아 앤드 업존 캄파니 | 중독성 질환의 치료용 화합물 |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| AR031152A1 (es) * | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
| US20040138200A1 (en) * | 2002-10-04 | 2004-07-15 | Michael Hawley | Pharmaceutical compositions for treatment of Parkinson's disease |
| AU2003277296A1 (en) * | 2002-10-04 | 2004-05-04 | Pharmacia Corporation | Compositions and methods for treating sexual dysfunction |
| CA2615007A1 (en) | 2005-07-13 | 2007-01-18 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives as 5-ht6,5-ht24 |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| ES2332645B1 (es) * | 2009-06-30 | 2010-10-18 | Grifols, S.A. | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
| DK2618826T3 (en) * | 2010-09-20 | 2016-08-01 | A Carlsson Res Ab | Phenylpiperdine FOR TREATMENT OF DEMENTIA |
| WO2014143768A1 (en) | 2013-03-15 | 2014-09-18 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| ES2635560T3 (es) | 2013-07-08 | 2017-10-04 | Incyte Holdings Corporation | Heterociclos tricíclicos como inhibidores de la proteína NET |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| ES2942723T3 (es) | 2014-04-23 | 2023-06-06 | Incyte Holdings Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET |
| DE102014008742A1 (de) * | 2014-06-12 | 2015-12-17 | Daimler Ag | Separator für einen elektrochemischen Speicher, Verfahren zur Herstellung eines Elektrodenmaterials sowie elektrochemischer Energiespeicher |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| CA2982898C (en) | 2015-05-13 | 2023-08-29 | A. Carlsson Research Ab | Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| KR20250163425A (ko) | 2016-06-20 | 2025-11-20 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| JP2955358B2 (ja) | 1989-06-09 | 1999-10-04 | ファルマシア・アンド・アップジョン・カンパニー | 中枢神経系活性を有する複素環系アミン |
| US5273975A (en) | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
| KR100196888B1 (ko) | 1991-04-17 | 1999-06-15 | 파마시아 앤드 업죤 컴패니 | 중추 작용성을 갖는 신규한 치환된 페닐아자사이클로 알칸 |
| JP3433804B2 (ja) | 1993-07-27 | 2003-08-04 | ファルマシア・アンド・アップジョン・カンパニー | 中枢神経系活性を有する複素環アミン類 |
| JPH1053525A (ja) * | 1996-06-06 | 1998-02-24 | Bitakain Seiyaku Kk | 疼痛治療剤 |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| WO2000054773A1 (en) * | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| KR20090087135A (ko) | 1999-07-01 | 2009-08-14 | 파마시아 앤드 업존 캄파니 엘엘씨 | 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 |
| DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| AU6917400A (en) * | 1999-08-31 | 2001-03-26 | Alcon Laboratories, Inc. | Use of 5-ht1b/1d agonists to treat otic pain |
-
2001
- 2001-04-17 CA CA002405565A patent/CA2405565A1/en not_active Abandoned
- 2001-04-17 BR BR0110210-9A patent/BR0110210A/pt not_active IP Right Cessation
- 2001-04-17 KR KR1020027014072A patent/KR20040007215A/ko not_active Withdrawn
- 2001-04-17 NZ NZ531172A patent/NZ531172A/en unknown
- 2001-04-17 ES ES01926590T patent/ES2253370T3/es not_active Expired - Lifetime
- 2001-04-17 DE DE60115872T patent/DE60115872T2/de not_active Expired - Fee Related
- 2001-04-17 CN CN01806849A patent/CN1450898A/zh active Pending
- 2001-04-17 CN CNA2004100476387A patent/CN1554343A/zh active Pending
- 2001-04-17 CN CNA2004100476391A patent/CN1554341A/zh active Pending
- 2001-04-17 NZ NZ531171A patent/NZ531171A/en unknown
- 2001-04-17 JP JP2001578433A patent/JP2004502650A/ja active Pending
- 2001-04-17 EP EP01926590A patent/EP1274430B1/en not_active Expired - Lifetime
- 2001-04-17 US US09/836,660 patent/US6448258B2/en not_active Expired - Fee Related
- 2001-04-17 DK DK01926590T patent/DK1274430T3/da active
- 2001-04-17 NZ NZ522112A patent/NZ522112A/en unknown
- 2001-04-17 AT AT01926590T patent/ATE312608T1/de not_active IP Right Cessation
- 2001-04-17 WO PCT/US2001/010807 patent/WO2001081343A2/en not_active Ceased
- 2001-04-17 AU AU5311401A patent/AU5311401A/xx active Pending
- 2001-04-17 AU AU2001253114A patent/AU2001253114B2/en not_active Ceased
- 2001-04-19 PE PE2001000357A patent/PE20011212A1/es not_active Application Discontinuation
- 2001-04-20 AR ARP010101861A patent/AR028355A1/es unknown
-
2002
- 2002-05-30 US US10/159,913 patent/US6555548B2/en not_active Expired - Fee Related
-
2003
- 2003-03-07 US US10/383,467 patent/US20030191149A1/en not_active Abandoned
- 2003-04-10 AR ARP030101259A patent/AR039633A2/es unknown
- 2003-04-10 AR ARP030101258A patent/AR039632A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60115872D1 (de) | 2006-01-19 |
| ES2253370T3 (es) | 2006-06-01 |
| US20030191149A1 (en) | 2003-10-09 |
| AU2001253114B2 (en) | 2005-08-25 |
| NZ531171A (en) | 2005-03-24 |
| BR0110210A (pt) | 2003-01-28 |
| CN1554343A (zh) | 2004-12-15 |
| AR039633A2 (es) | 2005-03-02 |
| CA2405565A1 (en) | 2001-11-01 |
| EP1274430A2 (en) | 2003-01-15 |
| US20020004510A1 (en) | 2002-01-10 |
| EP1274430B1 (en) | 2005-12-14 |
| AR028355A1 (es) | 2003-05-07 |
| ATE312608T1 (de) | 2005-12-15 |
| JP2004502650A (ja) | 2004-01-29 |
| US20020143010A1 (en) | 2002-10-03 |
| NZ522112A (en) | 2004-10-29 |
| WO2001081343A3 (en) | 2002-02-28 |
| DE60115872T2 (de) | 2006-07-13 |
| US6448258B2 (en) | 2002-09-10 |
| DK1274430T3 (da) | 2006-02-13 |
| CN1450898A (zh) | 2003-10-22 |
| US6555548B2 (en) | 2003-04-29 |
| AU5311401A (en) | 2001-11-07 |
| PE20011212A1 (es) | 2001-11-21 |
| CN1554341A (zh) | 2004-12-15 |
| KR20040007215A (ko) | 2004-01-24 |
| WO2001081343A2 (en) | 2001-11-01 |
| NZ531172A (en) | 2005-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039632A2 (es) | Uso de un compuesto tipo amina heterociclica para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
| DK0641320T3 (da) | Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister | |
| AR076753A1 (es) | Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides. | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| AR035325A1 (es) | Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento | |
| PE20200446A1 (es) | Nuevos inhibidores de hdac6 selectivos | |
| JP2016505619A5 (es) | ||
| FR2833948B1 (fr) | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament | |
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| PE20181348A1 (es) | PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y METODO DE USO | |
| AR062299A1 (es) | Derivados de bencimidazol | |
| AR036604A1 (es) | Derivados de 4-pirimidona 3-sustituida | |
| AR056347A1 (es) | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas | |
| HUP0301777A2 (hu) | Tiroidreceptor-ligandum anilin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| SV2009002925A (es) | Derivados de oxadiazol | |
| CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| AR082498A1 (es) | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide | |
| AR056519A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros | |
| RU2010107603A (ru) | Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний | |
| AR074700A1 (es) | Derivados heterociclicos fusionados con oxadiazola, composiciones farmaceuticas, procesos de preparacion y su uso en el tratamiento de esclerosis multiple y otras enfermedades | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| AR043741A1 (es) | 4-feniltetrahidroisoquinoleinas sustituidas, su uso como un medicamento, y el medicamento que las comprende | |
| RU2014114930A (ru) | Новая терапия транстиретин-ассоциированного амилоидоза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |